Navigation Links
Drug therapy for allergy moves forward
Date:5/12/2014

Researchers have identified several target molecules which are suitable for the development of new allergy drugs. The Journal of Allergy and Clinical Immunology, the most prestigious journal in the field of allergology, has recently published an extensive review article on the prospects of drug therapy for allergy. Completed in a large-scale EU project, the lead author of the review article is Professor Ilkka Harvima of the University of Eastern Finland and Kuopio University Hospital.

Immediate allergic reactions and allergic diseases such as allergic rhinitis, asthma and urticaria are extremely widespread in the population. Traditionally, drug therapy for allergy is based on the use of non-sedative antihistamines, i.e. blocking of the histamine H1 receptors, but sometimes additional help is obtained from blockers of the cysteinyl leukotriene receptor-1.

Antihistamines seek to prevent allergic symptoms caused by histamine released by mast cells. Mast cells, also known as "allergy cells", are cells of the immune system which become activated by environmental allergens.

"However, even high doses of H1 antihistamine drugs aren't enough to alleviate the symptoms of some patients. This is understandable, as when the mast cell becomes activated, several other strong mediators besides histamine get released, too. Histamine can also affect other receptors of the cell surface than the H1 receptor," Professor Harvima explains.

Over the past years, researchers have identified several mast cell molecules which can be targets of new drugs. Several of these have already proceeded to clinical trials. These targets include, for example, serine proteinases tryptase, chymase, cathepsin G, which are enzymes that break down proteins, as well as 5-lipoxygenase-activating protein FLAP, 15-lipoxygenase-1, prostaglandin-D2, and proinflammatory cytokines such as TNF-alpha, IL-4, IL-6 and IL-17. New drugs targeting the histamine H4 receptor are also undergoing clinical trials. In the near future, it is possible that drug therapy for allergy is a combination of H1 and H4 receptor blockers.

Several target molecules have also been identified in intracellular signalling pathways and in cell survival proteins. Inhibiting these molecules can lead to the prevention of activation of the cell and to the prevention of mediator release. Various receptors which can either activate or inhibit the cell have been identified on cell surface. Different drug molecules make it possible to affect the function of these receptors and, consequently, to prevent cell activation and mediator release.


'/>"/>

Contact: Ilkka Harvima
ilkka.harvima@kuh.fi
358-447-172-875
University of Eastern Finland
Source:Eurekalert

Related medicine news :

1. Two-lock box delivers cancer therapy
2. WHI reports $37.1B economic return on combined hormone therapy clinical trial
3. Study finds family-based exposure therapy effective treatment for young children with OCD
4. No credible evidence to support cardiac risk of testosterone therapy
5. Outcomes of steroid therapy following surgery for infants with bile duct disorder
6. New combination therapy developed for multiple myeloma
7. New model can predict therapy outcomes in prostate cancer with bone metastasis
8. Stress research in therapy dogs reveals animals needs
9. Receiving chemotherapy after a breast cancer diagnosis may affect a patients employment
10. ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer
11. Massage therapy improves circulation, eases muscle soreness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2020)... ... February 20, 2020 , ... R3 Stem Cell, the nation's leader in ... 70 complimentary stem cell procedures on military veterans in 2019. The veterans ... , At the R3 Stem Cell Training Course for doctors , providers of all ...
(Date:2/19/2020)... MANCHESTER, N.H. (PRWEB) , ... February 19, 2020 ... ... has been honored with a grant of $10,000.00 from the Doug Flutie, Jr. ... physical fitness program for students with autism. , The physical fitness program will ...
(Date:2/19/2020)... MIAMI (PRWEB) , ... February 19, 2020 , ... ... to the film industry. While he is most known for his acting abilities ... exceptional host on the educational show “Behind The Scenes” with Laurence Fishburne. “Behind ...
(Date:2/19/2020)... ... February 19, 2020 , ... BPM+ Health , a ... it will participate in the HIMSS20 Global Health Conference & Exhibition, ... professionals and other stakeholders at HIMSS20 – the largest global health information and ...
(Date:2/19/2020)... ... February 19, 2020 , ... SafiraMD ... CoolEvent for FDA-cleared CoolSculpting®, the world’s most popular non-invasive fat reduction treatment. Their ... in the Halcyon Village Center in Alpharetta, Georgia. The CoolEvent will feature live ...
Breaking Medicine News(10 mins):
(Date:2/19/2020)... , ... February 19, 2020 ... ... notebook platform for research data management, has released a new SnapGene ... data management features. With a ‘Quick View’ of supported DNA files, the ...
(Date:2/19/2020)... ... February 19, 2020 , ... The swine flu (H1N1) ... foot-and-mouth disease (FMD) is a potential new outbreak. Although the U.S. has eradicated ... more than two-thirds of countries in the world, posing a risk from trading partners. ...
(Date:2/15/2020)... ... 14, 2020 , ... Clean the World, a leader in global health dedicated ... customer portal for hospitality partners has enabled them to increase customer support capacity by ... allowed Clean the World to produce 5.8 million bars in 2019 – 2 million ...
Breaking Medicine Technology: